Is GH Worth Buying in 2026?

Guardant Health, Inc. Common Stock

STOCK SERVICES-MEDICAL LABORATORIES Updated 2026-08-16

Here’s whether Guardant Health, Inc. Common Stock (GH) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Bullish.

🟢
Bullish

Positives: trading above the 200-day MA (long-term uptrend intact); above the 50-day MA (medium-term momentum positive); 50-day MA is rising (+5.26% over 10 days); RSI 61 — healthy momentum range; strong 1-year return of +160.4%; 3-month momentum positive (+65.6%). Currently 11.0% off its 52-week high. Score: +7/7.

Ready to act on this? 📈 Trade on Webull

GH is in a confirmed uptrend, trading above both its 50-day ($149.58) and 200-day ($112.03) moving averages. An RSI of 60.6 sits in the neutral zone — momentum is neither stretched nor exhausted. The 1-year return of +160.4% compares to +20.4% for SPY (beat the market by 140.1%).

$10,000 invested 1 year ago → $26,045 today
vs. S&P 500 (SPY) — same period beat market by 140.1%

1-Year Price Chart

Daily candles
MA-50 MA-200 Up Down

Signal Check

Above 200-day MA ($112.03)
Above 50-day MA ($149.58)
RSI(14) neutral zone (30–70) — currently 60.6
Positive return (+160.4%)
!Within 10% of period high (−11.0%)
Period Range $157.21
$53.40 $176.58
RSI (14) 60.6
0 · OversoldOverbought · 100

Key Metrics

Price$157.21
Period Return+160.4%
Period High$176.58
Period Low$53.40
Drawdown−11.0%
MA-50$149.58
MA-200$112.03
RSI (14)60.6
Avg Volume (30d)2.1M
vs. SPYbeat by 140.1%
Return Rank#76 of 1252

Trade GH

📈 Trade on Webull 📊 Trade on moomoo 💹 Interactive Brokers